Delivery Order SPE2DB22D9112-SPE2DB24FE6TT
- Not listed
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $2,111.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 with DMS Pharmaceutical Group to provide a comprehensive range of pharmaceutical products, including branded and generic prescription...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,407.12 contract is to provide 4,564,856,921 units of Terbinafine HCl 250 mg tablets. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC allows the DLA to issue firm...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,055.34 firm fixed-price delivery order is for the supply of 4568644503 - TERBINAFINE HCL 250 MG TABLET 30S. The award has an ultimate completion date of June 26, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $16,240.51, was awarded on July 11, 2025 by the Defense Logistics Agency (DLA) to provide the U.S. government with 4568763716 - TERBINAFINE 250MG 30S, a pharmaceutical product. The contract has an ultimate completion date of July 11, 2025 and does not have a set-aside designation. DMS...
- This is a firm fixed-price delivery order for terbinafine hydrochloride 250 mg tablets, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $1,348.49 and a period of performance through July 14, 2025. DMS Pharmaceutical Group Inc. is an established pharmaceutical wholesaler that specializes in supplying a range of medical products, including branded and generic prescription...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $1,407.12 contract is for the delivery of 4,564,928,264 tablets of the prescription drug terbinafine hydrochloride 250 mg, with a performance period through May 17, 2024. The award is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical valued at up to $499,999,999. This IDC, part of the DLA's SPE2DB program, allows the...
- The Defense Logistics Agency awarded a delivery order valued at $1,172.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Terbinafine HCL 250 mg tablets in quantities of 30. The contract is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and was awarded on August 5, 2025, with no set-aside designation utilized. This award is issued under DMS Pharmaceutical Group's...
- On June 20, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $1,922.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order is for Terbinafine HCL 250 mg tablets in quantities of 30, with an ultimate completion date of June 23, 2025. This award utilizes a firm fixed-price contract structure with no set-aside designation applied. The delivery order falls under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,407.12 to DMS Pharmaceutical Group Inc. for Terbinafine HCL 250 mg tablets (30-count) on June 14, 2025, with an ultimate completion date of June 16, 2025. This firm fixed-price delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program, a $499.999 billion single-award vehicle valid through November 2026. The contract does not utilize a set-aside...
- The U.S. Defense Logistics Agency (DLA), operating under the Medical Supply Chain, awarded a delivery order valued at $14,293.82 to DMS Pharmaceutical Group Inc. for the supply of Terbinafine 250mg tablets (30-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform delivery at its Park Ridge facility. This delivery order utilizes a firm fixed-price contract structure with an ultimate completion date of...
- SPE2DB22D9112Indefinite Delivery Contract
- SPE2DB22D9112-SPE2DB24FE6TTDelivery Order
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,407.12 order is for 4564445549 - TERBINAFINE HCL 250 MG TABLET 30S. The order was issued under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract (IDC) with DLA, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. This single-award IDC, under the SPE2DB program, does not have a set-aside designation. DMS Pharmaceutical Group is a prime vendor providing direct distribution of prescription drugs and pharmacy services to the Department of Defense, complementing the pharmaceutical products supplied through this IDC vehicle. The company holds significant experience delivering a vast array of medications, including both common and specialized pharmaceutical products, to support the diverse medical needs of military personnel and their dependents across various DoD healthcare facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 4/26/24 |